Seminars in Oncology
Volume 35, Supplement 3 , Pages S13-S21, June 2008

Antitumor Activity of Vinflunine: Effector Pathways and Potential for Synergies

  • Diane Braguer

      Affiliations

    • INSERM UMR911, Centre de Recherche en Oncologie Biologique, et Oncopharmacologie; Aix-Marseille University, Marseille, France.
    • Corresponding Author InformationAddress correspondence to Diane Braguer, PhD, Faculte de Pharmacié, INSERM UMR 911, 27 Boulevard Jean Moulin, 13005 Marseille, France.
  • ,
  • Jean-Marc Barret

      Affiliations

    • Centre de Recherche d'Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France.
  • ,
  • Hayley McDaid

      Affiliations

    • Albert Einstein College of Medicine, Bronx, NY.
  • ,
  • Anna Kruczynski

      Affiliations

    • Centre de Recherche d'Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France.

Vinflunine is an innovative microtubule inhibitor of the vinca alkaloid class with distinct tubulin-binding properties. Preclinical evaluation of this novel microtubule inhibitor has shown superior antitumor activity against a broad spectrum of tumor types in vitro and in vivo, in comparison with other vinca alkaloids. The antitumor effect of vinflunine is largely attributable to its modulation of microtubule dynamics, and is mediated by its ability to induce apoptosis in target cells. At non-cytotoxic concentrations, vinflunine also exerts antiangiogenic and antivascular activity. The favorable preclinical profile of vinflunine, in addition to its synergism with a variety of other therapeutic modalities, justifies further clinical development of this compound.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr Braguer has no conflict of interest to declare. Dr McDaid has served as a consultant to Bristol-Myers Squibb. Drs Kruczynski and Barret are employees of the Institut de Recherche Pierre Fabre, a private pharmaceutical company supporting the development of vinflunine.

PII: S0093-7754(08)00023-7

doi:10.1053/j.seminoncol.2008.01.011

Seminars in Oncology
Volume 35, Supplement 3 , Pages S13-S21, June 2008